Neelesh S Bangalore, MD
Hematology · Tracy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
- Since medical school
- 41 years
- Graduated 1985
Offices
6 locations · Stockton Hematology Oncology Medical Group Inc · 9 clinicians in this group
Looking this up.
Hospitals listed: A01791 · St Joseph'S Medical Center of Stockton · Sutter Tracy Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bangalore’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A70883 · Current
Licensed to practise in California · since 2000 · expires 2027-08-31 · University of Bombay, Seth G. S. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
- Sutter Tracy Community HospitalTracy, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Tracy Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 2 better, 5 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.21 to 2.34) · 363 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.41 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 156 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.6 · 51 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 835 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,800 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,820 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.09 (0.6 to 5.57) · 291 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 138 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.51 to 3.87) · 274 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (0 to 17.04) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.93 (0.72 to 9.15) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.34) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.981 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.796 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.8 · 194 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -47.9 · 145 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.1 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.3 to 16.7) · 504 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 104 cases | No different | Jan 2024 – Dec 2024 |
What patients said (443 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$4,544,718
Medicare paid this office $4,544,718 for 611 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 120 | $250,002 | $1,389 |
| Injection, denosumab, 1 mg | 53 | $243,241 | None |
| Injection, eflapegrastim-xnst, 0.1 mg | 13 | $140,660 | None |
| Return visit (30+ min) | 457 | $122,483 | $96 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 13 | $69,638 | $516 |
See all 39 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 120 | $250,002 | $1,389 |
| Injection, denosumab, 1 mg | 53 | $243,241 | None |
| Injection, eflapegrastim-xnst, 0.1 mg | 13 | $140,660 | None |
| Return visit (30+ min) | 457 | $122,483 | $96 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 13 | $69,638 | $516 |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $55,099 | $109 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 111 | $47,911 | $282 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 13 | $32,232 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $27,000 | $60 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 15 | $15,942 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $11,612 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $9,306 | $93 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $8,855 | $54 |
| Short return visit (20+ min) | 95 | $8,679 | $66 |
| New patient visit (60+ min) | 54 | $8,612 | $159 |
| Injection of drug or substance under skin or into muscle | 92 | $6,807 | $11 |
| Long return visit (40+ min) | 40 | $6,106 | $139 |
| Injection of additional new drug or substance into vein | 53 | $5,516 | $13 |
| New patient visit (45+ min) | 45 | $5,359 | $119 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 105 | $5,350 | $8 |
| Injection, leucovorin calcium, per 50 mg | 13 | $5,205 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 23 | $5,032 | $51 |
| Administration of chemotherapy into vein, each additional hour | 34 | $4,821 | $23 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,270 | $131 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $2,563 | $29 |
| Injection, fluorouracil, 500 mg | 15 | $2,387 | None |
| Insertion of needle into vein for collection of blood sample | 92 | $1,999 | $7 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,618 | $27 |
| New patient visit (30+ min) | 18 | $1,548 | $86 |
| Irrigation of implanted venous access drug delivery device | 27 | $1,535 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $1,499 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,490 | $62 |
| Injection, carboplatin, 50 mg | 14 | $1,457 | None |
| Injection, oxaliplatin, 0.5 mg | 13 | $1,255 | None |
| Infusion into a vein for hydration, each additional hour | 23 | $1,022 | $10 |
| Injection, palonosetron hcl, 25 mcg | 23 | $987 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 43 | $256 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 48 | $171 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 23 | $104 | None |
Who their Medicare patients are
611 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 10% · Women 58% · Also on Medicaid 48% · Health risk score 2.04. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 75% · Diabetes 46% · Cancer 44% · Chronic kidney disease 43% · Coronary heart disease 31% · Heart failure 23% · COPD 22% · Depression 20% · Atrial fibrillation 19% · Stroke 9% · Dementia 7%.
The office billed $16,464,445, Medicare allowed $5,724,927 and paid $4,544,718; for 270,453 services of 112 kinds; $3,809,483 of it was for drugs given in the office and $735,235 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 611 | 270,453 | 73 | 2.04 | $16,464,445 | $4,544,718 |
| 2023 | 656 | 219,870 | 73 | 2.19 | $17,395,362 | $3,955,628 |
| 2022 | 566 | 179,208 | 72 | 2.10 | $17,928,929 | $3,477,946 |
| 2021 | 598 | 228,024 | 73 | 2.12 | $18,024,681 | $3,737,256 |
| 2020 | 576 | 270,994 | 72 | 2.13 | $11,159,075 | $3,369,064 |
| 2019 | 620 | 228,574 | 72 | 2.21 | $8,754,919 | $2,839,764 |
| 2018 | 580 | 130,517 | 72 | 2.36 | $4,151,277 | $1,995,307 |
| 2017 | 556 | 198,326 | 72 | 2.29 | $3,355,105 | $2,038,767 |
| 2016 | 554 | 218,559 | 71 | 2.26 | $3,016,886 | $1,833,745 |
| 2015 | 546 | 120,352 | 72 | 2.27 | $2,717,378 | $1,661,445 |
| 2014 | 594 | 115,166 | 71 | 2.19 | $2,939,621 | $1,790,467 |
| 2013 | 604 | 100,448 | 71 | 2.15 | $3,139,129 | $1,832,235 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 37 services
| Injection, denosumab, 1 mg | 46 | $251,243 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 115 | $225,343 | $1,382 |
| Return visit (30+ min) | 422 | $102,143 | $98 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 18 | $83,676 | $489 |
| Administration of chemotherapy into vein, 1 hour or less | 54 | $45,433 | $110 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 101 | $41,816 | $279 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 113 | $19,543 | $97 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 11 | $14,910 | None |
| New patient visit (60+ min) | 75 | $12,847 | $171 |
| Short return visit (20+ min) | 135 | $12,181 | $68 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $10,874 | $147 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $7,226 | $24 |
| Long return visit (40+ min) | 43 | $7,018 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $6,123 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $5,516 | $141 |
| Injection of drug or substance under skin or into muscle | 77 | $5,062 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $5,022 | $52 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 81 | $4,524 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,258 | $64 |
| Administration of chemotherapy into vein, each additional hour | 32 | $4,140 | $24 |
| Injection of additional new drug or substance into vein | 40 | $4,000 | $13 |
| New patient visit (45+ min) | 33 | $3,850 | $117 |
| Injection, leucovorin calcium, per 50 mg | 12 | $3,316 | None |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,012 | $47 |
| Insertion of needle into vein for collection of blood sample | 62 | $2,245 | $8 |
| Irrigation of implanted venous access drug delivery device | 22 | $1,429 | $20 |
| Injection, fluorouracil, 500 mg | 12 | $1,335 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $1,335 | $16 |
| New patient visit (30+ min) | 13 | $1,112 | $86 |
| Injection, oxaliplatin, 0.5 mg | 12 | $1,099 | None |
| Infusion into a vein for hydration, each additional hour | 18 | $1,000 | $11 |
| Injection, palonosetron hcl, 25 mcg | 16 | $713 | None |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $673 | $28 |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $182 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $159 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $49 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $43 | None |
2022: 30 services
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 12 | $241,499 | $28 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 86 | $177,349 | $1,386 |
| Injection, denosumab, 1 mg | 31 | $164,705 | None |
| Return visit (30+ min) | 344 | $81,741 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 56 | $53,855 | $117 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 87 | $36,608 | $282 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 16 | $22,362 | None |
| Short return visit (20+ min) | 159 | $16,915 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $12,680 | $83 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 11 | $11,919 | $147 |
| Long return visit (40+ min) | 64 | $11,611 | $142 |
| New patient visit (60+ min) | 65 | $11,540 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $8,751 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $7,889 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $6,781 | $57 |
| New patient visit (45+ min) | 52 | $6,019 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $4,827 | $58 |
| Injection of additional new drug or substance into vein | 39 | $3,923 | $13 |
| Injection of drug or substance under skin or into muscle | 53 | $3,917 | $12 |
| Administration of chemotherapy into vein, each additional hour | 27 | $3,349 | $25 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,078 | $110 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 81 | $2,926 | $8 |
| Irrigation of implanted venous access drug delivery device | 26 | $1,936 | $22 |
| Injection, fluorouracil, 500 mg | 11 | $1,159 | None |
| Injection, carboplatin, 50 mg | 13 | $840 | None |
| Injection, palonosetron hcl, 25 mcg | 15 | $694 | None |
| Insertion of needle into vein for collection of blood sample | 55 | $483 | $3 |
| Infusion into a vein for hydration, each additional hour | 12 | $418 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $190 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $141 | None |
2021: 40 services
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 13 | $357,355 | $40 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 106 | $215,764 | $1,357 |
| Injection, denosumab, 1 mg | 26 | $169,707 | None |
| Return visit (30+ min) | 330 | $87,647 | $103 |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $80,138 | $125 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 107 | $41,771 | $261 |
| Short return visit (20+ min) | 251 | $33,950 | $67 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 16 | $28,229 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $16,866 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $15,970 | $84 |
| Long return visit (40+ min) | 78 | $15,803 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $13,122 | $26 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $11,555 | $60 |
| New patient visit (60+ min) | 58 | $10,179 | $175 |
| New patient visit (45+ min) | 62 | $7,122 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $6,841 | $163 |
| Injection of additional new drug or substance into vein | 45 | $6,544 | $14 |
| Administration of chemotherapy into vein, each additional hour | 35 | $6,455 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $6,025 | $58 |
| Injection of drug or substance under skin or into muscle | 53 | $5,891 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 24 | $4,958 | $60 |
| Administration of additional new drug or substance into vein using push technique | 13 | $4,741 | $52 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 104 | $4,718 | $8 |
| Injection, leucovorin calcium, per 50 mg | 11 | $3,759 | None |
| Injection, palonosetron hcl, 25 mcg | 23 | $3,063 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,917 | $28 |
| Irrigation of implanted venous access drug delivery device | 24 | $1,915 | $24 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; second dose | 45 | $1,672 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $1,639 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,372 | $30 |
| Injection, fluorouracil, 500 mg | 12 | $1,344 | None |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose | 47 | $1,267 | $27 |
| Injection, carboplatin, 50 mg | 18 | $1,106 | None |
| Infusion into a vein for hydration, each additional hour | 17 | $781 | $12 |
| Insertion of needle into vein for collection of blood sample | 60 | $570 | $3 |
| Short return visit | 15 | $518 | $35 |
| Injection, dexamethasone sodium phosphate, 1 mg | 45 | $395 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $129 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $90 | None |
| Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage, for intramuscular use | 49 | $1 | $0 |
2020: 40 services
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 11 | $256,578 | $49 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 108 | $244,015 | $1,326 |
| Injection, bevacizumab, 10 mg | 12 | $243,361 | None |
| Injection, denosumab, 1 mg | 21 | $127,910 | None |
| Administration of chemotherapy into vein, 1 hour or less | 67 | $84,870 | $120 |
| Return visit (30+ min) | 265 | $56,072 | $83 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 14 | $42,984 | $0 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 108 | $36,845 | $199 |
| Short return visit (20+ min) | 268 | $33,664 | $59 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $23,364 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 54 | $16,822 | $26 |
| Injection, aprepitant, 1 mg | 19 | $16,493 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $15,888 | $58 |
| Long return visit (40+ min) | 90 | $13,514 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $13,026 | $85 |
| New patient visit (60+ min) | 68 | $10,442 | $154 |
| Injection, palonosetron hcl, 25 mcg | 38 | $9,933 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,351 | $167 |
| Administration of chemotherapy into vein, each additional hour | 41 | $9,177 | $26 |
| Injection of additional new drug or substance into vein | 53 | $9,040 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $8,527 | $60 |
| Administration of additional new drug or substance into vein using push technique | 18 | $8,125 | $50 |
| Injection of drug or substance under skin or into muscle | 53 | $5,880 | $12 |
| Injection, leucovorin calcium, per 50 mg | 18 | $5,050 | None |
| Injection, irinotecan, 20 mg | 12 | $4,152 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $3,869 | $60 |
| New patient visit (45+ min) | 25 | $3,176 | $127 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 80 | $2,903 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $2,726 | $18 |
| Irrigation of implanted venous access drug delivery device | 25 | $2,670 | $23 |
| Injection, fluorouracil, 500 mg | 19 | $2,004 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $1,512 | None |
| Injection, carboplatin, 50 mg | 13 | $1,000 | None |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $609 | $29 |
| Infusion into a vein for hydration, each additional hour | 15 | $592 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $443 | None |
| Insertion of needle into vein for collection of blood sample | 54 | $361 | $3 |
| Injection, atropine sulfate, 0.01 mg | 12 | $294 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $140 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $71 | None |
2019: 40 services
| Injection, bevacizumab, 10 mg | 15 | $513,865 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 130 | $220,905 | $1,255 |
| Injection, denosumab, 1 mg | 21 | $91,490 | None |
| Return visit (30+ min) | 347 | $73,732 | $82 |
| Administration of chemotherapy into vein, 1 hour or less | 70 | $73,146 | $116 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 15 | $47,552 | $0 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 129 | $35,091 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $24,227 | $84 |
| Long return visit (40+ min) | 135 | $23,869 | $117 |
| Injection, palonosetron hcl, 25 mcg | 43 | $21,736 | None |
| New patient visit (60+ min) | 128 | $20,319 | $159 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 14 | $19,088 | $139 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 64 | $15,429 | $26 |
| Injection, aprepitant, 1 mg | 16 | $14,838 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $12,819 | $57 |
| Short return visit (20+ min) | 104 | $11,868 | $57 |
| Injection of additional new drug or substance into vein | 64 | $8,443 | $14 |
| Administration of chemotherapy into vein, each additional hour | 41 | $6,878 | $25 |
| Injection of drug or substance under skin or into muscle | 59 | $6,622 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,921 | $160 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $5,902 | $58 |
| Administration of additional new drug or substance into vein using push technique | 13 | $5,679 | $49 |
| Injection, leucovorin calcium, per 50 mg | 12 | $3,618 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $2,341 | $18 |
| New patient visit (45+ min) | 18 | $2,178 | $121 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 69 | $2,073 | $8 |
| Irrigation of implanted venous access drug delivery device | 25 | $1,827 | $22 |
| Injection, paclitaxel, 1 mg | 13 | $1,724 | None |
| Injection, fluorouracil, 500 mg | 14 | $1,659 | None |
| Injection, carboplatin, 50 mg | 20 | $1,380 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $1,056 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $867 | $32 |
| Infusion into a vein for hydration, each additional hour | 22 | $838 | $11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 40 | $796 | $7 |
| Insertion of needle into vein for collection of blood sample | 70 | $635 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $344 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $163 | None |
| Infusion, normal saline solution , 1000 cc | 17 | $60 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $45 | None |
| Injection, lorazepam, 2 mg | 16 | $39 | None |
2018: 30 services
| Injection, pegfilgrastim, 6 mg | 11 | $96,352 | None |
| Return visit (30+ min) | 361 | $80,593 | $80 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $63,084 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 145 | $34,551 | $84 |
| Injection, palonosetron hcl, 25 mcg | 31 | $32,880 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 23 | $30,158 | $1,257 |
| Long return visit (40+ min) | 126 | $21,375 | $113 |
| New patient visit (60+ min) | 97 | $15,390 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $11,939 | $26 |
| Short return visit (20+ min) | 99 | $11,205 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,032 | $164 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $7,522 | $57 |
| Injection of additional new drug or substance into vein | 50 | $6,686 | $15 |
| Administration of chemotherapy into vein, each additional hour | 35 | $5,756 | $26 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $4,900 | $196 |
| Injection of drug or substance under skin or into muscle | 34 | $3,745 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $3,564 | $58 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $2,690 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 73 | $2,674 | $8 |
| New patient visit (45+ min) | 21 | $2,547 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 21 | $2,080 | $17 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $1,717 | $143 |
| Irrigation of implanted venous access drug delivery device | 16 | $1,180 | $23 |
| Insertion of needle into vein for collection of blood sample | 73 | $1,003 | $3 |
| Infusion into a vein for hydration, each additional hour | 19 | $889 | $12 |
| Injection, carboplatin, 50 mg | 11 | $674 | None |
| Short return visit | 13 | $508 | $36 |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $301 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $95 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $48 | None |
2017: 32 services
| Injection, rituximab, 100 mg | 11 | $181,477 | None |
| Return visit (30+ min) | 355 | $84,316 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $53,530 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $38,109 | $84 |
| Injection, palonosetron hcl, 25 mcg | 41 | $32,191 | None |
| Long return visit (40+ min) | 133 | $22,637 | $117 |
| New patient visit (60+ min) | 109 | $17,514 | $161 |
| Short return visit (20+ min) | 101 | $15,063 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,016 | $162 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 58 | $10,908 | $26 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $10,370 | $55 |
| Injection of drug or substance under skin or into muscle | 36 | $9,163 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $7,764 | $58 |
| Administration of chemotherapy into vein, each additional hour | 40 | $7,375 | $24 |
| Injection of additional new drug or substance into vein | 52 | $7,216 | $19 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,314 | $53 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 62 | $2,659 | $9 |
| New patient visit (45+ min) | 19 | $2,257 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 36 | $1,997 | $17 |
| Biopsy of bone marrow | 13 | $1,967 | $141 |
| Injection, paclitaxel, 1 mg | 14 | $1,815 | None |
| Injection, carboplatin, 50 mg | 21 | $1,582 | None |
| Infusion into a vein for hydration, each additional hour | 21 | $908 | $13 |
| Insertion of needle into vein for collection of blood sample | 62 | $891 | $3 |
| Irrigation of implanted venous access drug delivery device | 11 | $758 | $21 |
| Short return visit | 14 | $469 | $33 |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $233 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 13 | $133 | $10 |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $99 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $29 | None |
| Injection, lorazepam, 2 mg | 12 | $19 | None |
| Infusion, normal saline solution, 250 cc | 13 | $18 | None |
2016: 36 services
| Return visit (30+ min) | 345 | $87,935 | $84 |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $73,025 | $113 |
| Injection, tbo-filgrastim, 1 microgram | 11 | $60,804 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 126 | $36,637 | $84 |
| Injection, palonosetron hcl, 25 mcg | 37 | $26,440 | None |
| Long return visit (40+ min) | 132 | $23,057 | $113 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 56 | $22,851 | $57 |
| New patient visit (60+ min) | 138 | $22,716 | $165 |
| Short return visit (20+ min) | 128 | $20,111 | $58 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $18,656 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $14,285 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $13,386 | $53 |
| Injection of drug or substance under skin or into muscle | 36 | $11,957 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $10,590 | $26 |
| Administration of chemotherapy into vein, each additional hour | 50 | $10,259 | $24 |
| Administration of prolonged chemotherapy into vein | 13 | $9,440 | $118 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 116 | $4,962 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $3,726 | $48 |
| Biopsy of bone marrow | 23 | $3,537 | $141 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,459 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 21 | $2,702 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 90 | $2,356 | $9 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $2,012 | $26 |
| Injection, carboplatin, 50 mg | 23 | $1,778 | None |
| Insertion of needle into vein for collection of blood sample | 155 | $1,758 | $3 |
| Injection, paclitaxel, 1 mg | 13 | $1,452 | None |
| Infusion into a vein for hydration, each additional hour | 14 | $1,422 | $13 |
| Injection, fluorouracil, 500 mg | 14 | $1,113 | None |
| Irrigation of implanted venous access drug delivery device | 18 | $1,097 | $21 |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,042 | $69 |
| Short return visit | 24 | $897 | $36 |
| Injection of additional new drug or substance into vein | 12 | $717 | $19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 58 | $367 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $237 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 36 | $103 | None |
| Infusion, normal saline solution, 250 cc | 12 | $39 | None |
2015: 32 services
| Injection, bevacizumab, 10 mg | 14 | $400,740 | None |
| Return visit (30+ min) | 381 | $97,544 | $84 |
| Injection, denosumab, 1 mg | 13 | $63,615 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $62,747 | $113 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 70 | $33,423 | $58 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $27,260 | None |
| Injection, palonosetron hcl, 25 mcg | 31 | $26,397 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 95 | $23,441 | $85 |
| Long return visit (40+ min) | 133 | $21,331 | $116 |
| New patient visit (60+ min) | 128 | $20,832 | $163 |
| Short return visit (20+ min) | 112 | $16,875 | $59 |
| Administration of prolonged chemotherapy into vein | 13 | $13,336 | $118 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $12,515 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $11,535 | $165 |
| Administration of chemotherapy into vein, each additional hour | 29 | $8,848 | $24 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 133 | $7,799 | $10 |
| Injection of drug or substance under skin or into muscle | 36 | $7,633 | $21 |
| Administration of additional new drug or substance into vein using push technique | 14 | $5,922 | $52 |
| Injection, leucovorin calcium, per 50 mg | 11 | $3,387 | None |
| Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes | 12 | $2,298 | $177 |
| Injection, carboplatin, 50 mg | 16 | $2,254 | None |
| Injection, paclitaxel, 1 mg | 15 | $1,928 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,793 | $15 |
| Irrigation of implanted venous access drug delivery device | 16 | $1,752 | $21 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,665 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $1,603 | $25 |
| Injection, fluorouracil, 500 mg | 14 | $1,393 | None |
| Insertion of needle into vein for collection of blood sample | 103 | $1,247 | $3 |
| Short return visit | 19 | $688 | $36 |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $283 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 25 | $142 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $121 | None |
2014: 34 services
| Injection, bevacizumab, 10 mg | 16 | $437,717 | None |
| Injection, rituximab, 100 mg | 11 | $169,307 | None |
| Return visit (30+ min) | 395 | $99,958 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 71 | $69,551 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 142 | $40,751 | $84 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 87 | $31,236 | $55 |
| New patient visit (60+ min) | 170 | $27,942 | $164 |
| Injection, palonosetron hcl, 25 mcg | 40 | $25,148 | None |
| Long return visit (40+ min) | 139 | $21,620 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $21,126 | $163 |
| Short return visit (20+ min) | 147 | $20,006 | $57 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $17,162 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 46 | $11,423 | $51 |
| Administration of chemotherapy into vein, each additional hour | 47 | $10,182 | $23 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 164 | $8,481 | $10 |
| Administration of prolonged chemotherapy into vein | 11 | $8,441 | $116 |
| Injection of drug or substance under skin or into muscle | 34 | $6,697 | $20 |
| Administration of additional new drug or substance into vein using push technique | 15 | $4,158 | $51 |
| Biopsy of bone marrow | 20 | $2,783 | $139 |
| Injection, paclitaxel, 30 mg | 17 | $2,637 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $2,318 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $2,010 | $25 |
| Insertion of needle into vein for collection of blood sample | 121 | $1,529 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,492 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,387 | $15 |
| Aspiration of bone marrow sample for diagnosis | 19 | $1,276 | $67 |
| Injection, carboplatin, 50 mg | 18 | $1,074 | None |
| Short return visit | 25 | $931 | $36 |
| Injection, fluorouracil, 500 mg | 14 | $922 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $749 | $20 |
| Collection of blood sample from implanted device | 13 | $315 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $278 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $201 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $139 | None |
2013: 35 services
| Injection, rituximab, 100 mg | 15 | $200,462 | None |
| Return visit (30+ min) | 378 | $99,369 | $82 |
| Administration of chemotherapy into vein, 1 hour or less | 76 | $80,328 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 96 | $43,305 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $40,430 | $81 |
| Injection, zoledronic acid (zometa), 1 mg | 12 | $34,333 | None |
| New patient visit (60+ min) | 185 | $29,556 | $160 |
| Short return visit (20+ min) | 164 | $24,738 | $56 |
| Injection, palonosetron hcl, 25 mcg | 36 | $24,132 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 117 | $22,151 | $157 |
| Zoldedronic acid 1mg | 12 | $21,104 | $138 |
| Long return visit (40+ min) | 128 | $21,025 | $115 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $19,657 | None |
| Cyclophosphamide, 100 mg | 12 | $16,458 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 45 | $16,433 | $60 |
| Administration of chemotherapy into vein, each additional hour | 53 | $12,877 | $26 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 219 | $11,900 | $11 |
| Administration of additional new drug or substance into vein using push technique | 16 | $8,547 | $53 |
| Injection of drug or substance under skin or into muscle | 41 | $6,765 | $21 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $4,431 | $49 |
| Collection of blood sample from implanted device | 39 | $3,674 | $20 |
| Injection, paclitaxel, 30 mg | 15 | $3,586 | None |
| Biopsy of bone marrow | 20 | $2,789 | $139 |
| Insertion of needle into vein for collection of blood sample | 200 | $2,429 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 21 | $1,986 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $1,427 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $1,399 | $18 |
| Aspiration of bone marrow sample for diagnosis | 19 | $1,302 | $69 |
| Infusion into a vein for hydration, each additional hour | 18 | $1,266 | $13 |
| Injection, carboplatin, 50 mg | 21 | $1,244 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $919 | $20 |
| Short return visit | 20 | $721 | $36 |
| Injection, ondansetron hydrochloride, per 1 mg | 43 | $435 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 63 | $288 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $152 | None |
Medicaid work
$432,778 in 2024
Medicaid paid $432,778 for 3,877 billed services this clinician did in 2024, up to 135 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 205 | $237,569 |
| Return visit (30+ min) | 1,203 | $50,971 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 119 | $38,303 |
| Denosumab injection | 12 | $31,783 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 336 | $13,961 |
| Injection, dexamethasone sodium phosphate, 1 mg | 309 | $12,708 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 377 | $11,696 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 266 | $8,055 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 66 | $4,935 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 269 | $4,660 |
| Short return visit (20+ min) | 127 | $3,676 |
| New patient visit (45+ min) | 40 | $3,434 |
| 2024 | 3,877 | 19 | 135 | $432,778 |
| 2023 | 3,299 | 17 | 126 | $501,026 |
| 2022 | 2,964 | 15 | 87 | $411,973 |
| 2021 | 3,259 | 17 | 82 | $644,969 |
| 2020 | 5,280 | 17 | 87 | $452,054 |
| 2019 | 4,749 | 18 | 88 | $811,842 |
| 2018 | 4,709 | 16 | 107 | $772,658 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 243 | $293,625 |
| Denosumab injection | 24 | $52,415 |
| Return visit (30+ min) | 1,154 | $47,139 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 137 | $46,813 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 372 | $9,365 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 62 | $8,491 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 182 | $7,695 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 146 | $6,731 |
| New patient visit (60+ min) | 51 | $5,538 |
| Short return visit (20+ min) | 202 | $5,322 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 291 | $4,833 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 174 | $4,601 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 217 | $245,152 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 132 | $40,470 |
| Return visit (30+ min) | 864 | $38,175 |
| Denosumab injection | 15 | $33,493 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 288 | $13,559 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 425 | $11,749 |
| Injection, dexamethasone sodium phosphate, 1 mg | 239 | $10,396 |
| Short return visit (20+ min) | 185 | $5,334 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 245 | $4,944 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 146 | $3,128 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 22 | $1,651 |
| New patient visit (60+ min) | 13 | $1,365 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 266 | $296,822 |
| Denosumab injection | 70 | $199,428 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 199 | $59,377 |
| Return visit (30+ min) | 849 | $39,934 |
| Short return visit (20+ min) | 439 | $11,849 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 532 | $11,160 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 160 | $5,814 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 380 | $4,954 |
| Injection, dexamethasone sodium phosphate, 1 mg | 82 | $3,526 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 58 | $2,826 |
| Long return visit (40+ min) | 39 | $2,326 |
| New patient visit (60+ min) | 18 | $2,050 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 248 | $268,610 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 131 | $35,879 |
| Denosumab injection | 12 | $29,506 |
| Return visit (30+ min) | 746 | $28,788 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 474 | $14,156 |
| Palonosetron hcl | 275 | $13,594 |
| Short return visit (20+ min) | 568 | $13,332 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 675 | $12,456 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 713 | $9,705 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 456 | $7,899 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 209 | $5,000 |
| Injection, dexamethasone sodium phosphate, 1 mg | 416 | $4,016 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 387 | $474,370 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 246 | $87,484 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 641 | $66,391 |
| Palonosetron hcl | 284 | $56,502 |
| Return visit (30+ min) | 916 | $54,463 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 478 | $18,346 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 413 | $9,858 |
| Long return visit (40+ min) | 141 | $9,433 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 183 | $9,010 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 53 | $7,807 |
| Injection, dexamethasone sodium phosphate, 1 mg | 435 | $5,340 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 129 | $3,539 |
2018
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 892 | $501,420 |
| Palonosetron hcl | 250 | $72,019 |
| Return visit (30+ min) | 1,085 | $63,549 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 43 | $53,279 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 576 | $20,445 |
| Long return visit (40+ min) | 202 | $18,947 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 469 | $14,004 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 28 | $10,421 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 221 | $7,737 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 30 | $3,587 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 160 | $2,698 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 71 | $1,900 |
Drugs they prescribed that Part D paid
$7,892,064
Pharmacies billed $7,892,064 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 22% of their Part D prescriptions (667 of 3,100) in 2024. A higher opioid share than 9 in 10 peers; the typical hematology clinician is at 4%. Long-acting opioids: 14% of their opioid prescriptions.
2,484 generic and fewer than 11 brand-name prescriptions · $7,892,064 in drug cost · 78 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 67 | $1,273,612 | $19,009 |
| Lenalidomide | 83 | $1,196,486 | $14,415 |
| Ibrance | 56 | $868,569 | $15,510 |
| Xtandi | 48 | $665,454 | $13,864 |
| Jakafi | 27 | $507,606 | $18,800 |
See all 67 drugs
| Pomalyst | 67 | $1,273,612 | $19,009 |
| Lenalidomide | 83 | $1,196,486 | $14,415 |
| Ibrance | 56 | $868,569 | $15,510 |
| Xtandi | 48 | $665,454 | $13,864 |
| Jakafi | 27 | $507,606 | $18,800 |
| Lynparza | 30 | $487,914 | $16,264 |
| Tagrisso | 28 | $435,560 | $15,556 |
| Sprycel | 25 | $374,134 | $14,965 |
| Brukinsa | 16 | $226,672 | $14,167 |
| Imbruvica | 13 | $212,751 | $16,365 |
| Verzenio | 14 | $211,578 | $15,113 |
| Abiraterone Acetate | 32 | $107,711 | $3,366 |
| Venclexta | 11 | $106,092 | $9,645 |
| Eliquis | 90 | $74,618 | $829 |
| Procrit | 30 | $70,352 | $2,345 |
| Hydrocodone-Acetaminophen | 407 | $13,014 | $32 |
| Xarelto | 19 | $12,456 | $656 |
| Imatinib Mesylate | 11 | $6,946 | $631 |
| Fulvestrant | 12 | $6,305 | $525 |
| Letrozole | 246 | $5,134 | $21 |
| Lamivudine Hbv | 11 | $4,821 | $438 |
| Fentanyl | 11 | $3,271 | $297 |
| Hydroxyurea | 68 | $1,845 | $27 |
| Morphine Sulfate Er | 47 | $1,541 | $33 |
| Oxycodone | 74 | $1,534 | $21 |
| Megestrol Acetate | 29 | $1,522 | $52 |
| Methadone | 28 | $1,244 | $44 |
| Ondansetron Odt | 72 | $1,045 | $15 |
| Prochlorperazine Maleate | 72 | $1,007 | $14 |
| Oxycodone-Acetaminophen | 32 | $962 | $30 |
| Anastrozole | 41 | $799 | $19 |
| Acyclovir | 66 | $707 | $11 |
| Dexamethasone | 57 | $644 | $11 |
| Tamoxifen Citrate | 24 | $639 | $27 |
| Gabapentin | 43 | $585 | $14 |
| Bicalutamide | 39 | $579 | $15 |
| Hydrocortisone | 13 | $563 | $43 |
| Venlafaxine Hcl Er | 27 | $555 | $21 |
| Levothyroxine | 42 | $495 | $12 |
| Prednisone | 69 | $422 | $6 |
| Baclofen | 32 | $399 | $12 |
| Lidocaine-Prilocaine | 29 | $361 | $12 |
| Alprazolam | 72 | $359 | $5 |
| Diphenoxylate-Atropine | 17 | $352 | $21 |
| Lorazepam | 64 | $344 | $5 |
| Hydromorphone | 28 | $339 | $12 |
| Morphine Sulfate | 17 | $280 | $16 |
| Lactulose | 15 | $265 | $18 |
| Nystatin | 12 | $229 | $19 |
| Loperamide | 18 | $209 | $12 |
| Nitrofurantoin | 12 | $190 | $16 |
| Omeprazole | 26 | $170 | $7 |
| Sulfamethoxazole-Trimethoprim | 48 | $127 | $3 |
| Allopurinol | 24 | $75 | $3 |
| Amlodipine Besylate | 35 | $72 | $2 |
| Tramadol | 15 | $68 | $5 |
| Ibuprofen | 11 | $68 | $6 |
| Trazodone | 15 | $62 | $4 |
| Ondansetron | 14 | $62 | $4 |
| Potassium Chloride | 13 | $61 | $5 |
| Famotidine | 24 | $48 | $2 |
| Diazepam | 27 | $40 | $1 |
| Zolpidem | 29 | $33 | $1 |
| Folic Acid | 11 | $32 | $3 |
| Alendronate | 13 | $27 | $2 |
| Carisoprodol | 13 | $24 | $2 |
| Simvastatin | 12 | $11 | $1 |
Year by year
| 2024 | 3,100 | 376 | 22% (667) | None | $7,892,064 |
| 2023 | 3,072 | 356 | 20% (624) | 18% | $7,107,932 |
| 2022 | 2,671 | 309 | 23% (616) | 19% | $5,787,355 |
| 2021 | 2,883 | 335 | 24% (678) | None | $5,513,826 |
| 2020 | 2,590 | 322 | 25% (647) | 16% | $4,219,802 |
| 2019 | 2,459 | 299 | 23% (573) | 17% | $3,599,182 |
| 2018 | 2,443 | 269 | 22% (537) | 19% | $4,166,899 |
| 2017 | 2,164 | 267 | 20% (439) | None | $2,807,068 |
| 2016 | 2,320 | 257 | 21% (490) | None | $2,025,403 |
| 2015 | 2,213 | 243 | 24% (539) | None | $1,505,616 |
| 2014 | 2,317 | 256 | 26% (598) | None | $1,430,285 |
| 2013 | 2,441 | 252 | 26% (631) | None | $1,500,721 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 60 drugs
| Lenalidomide | 64 | $818,388 | $12,787 |
| Xtandi | 51 | $749,030 | $14,687 |
| Pomalyst | 32 | $717,570 | $22,424 |
| Ibrance | 45 | $713,237 | $15,850 |
| Lynparza | 39 | $636,600 | $16,323 |
| Tagrisso | 30 | $521,896 | $17,397 |
| Revlimid | 32 | $519,800 | $16,244 |
| Jakafi | 25 | $453,475 | $18,139 |
| Sprycel | 17 | $299,818 | $17,636 |
| Abiraterone Acetate | 42 | $209,198 | $4,981 |
| Imbruvica | 13 | $206,655 | $15,897 |
| Verzenio | 12 | $175,276 | $14,606 |
| Mekinist | 11 | $100,605 | $9,146 |
| Eliquis | 96 | $65,995 | $687 |
| Xarelto | 27 | $19,384 | $718 |
| Hydrocodone-Acetaminophen | 369 | $16,525 | $45 |
| Letrozole | 226 | $11,383 | $50 |
| Fulvestrant | 15 | $10,383 | $692 |
| Fentanyl | 27 | $5,132 | $190 |
| Megestrol Acetate | 39 | $2,848 | $73 |
| Imatinib Mesylate | 13 | $2,203 | $169 |
| Oxycodone | 52 | $2,160 | $42 |
| Hydroxyurea | 72 | $1,720 | $24 |
| Tamoxifen Citrate | 36 | $1,655 | $46 |
| Alprazolam | 80 | $1,623 | $20 |
| Methadone | 30 | $1,617 | $54 |
| Lorazepam | 87 | $1,605 | $18 |
| Gabapentin | 59 | $1,586 | $27 |
| Acyclovir | 70 | $1,485 | $21 |
| Prochlorperazine Maleate | 91 | $1,402 | $15 |
| Anastrozole | 40 | $1,306 | $33 |
| Dexamethasone | 69 | $1,287 | $19 |
| Ondansetron Odt | 64 | $1,131 | $18 |
| Baclofen | 26 | $1,036 | $40 |
| Prednisone | 84 | $898 | $11 |
| Bicalutamide | 44 | $807 | $18 |
| Hydromorphone | 37 | $803 | $22 |
| Oxycodone-Acetaminophen | 45 | $793 | $18 |
| Levothyroxine | 56 | $782 | $14 |
| Venlafaxine Hcl Er | 12 | $539 | $45 |
| Zolpidem | 27 | $499 | $18 |
| Morphine Sulfate | 20 | $457 | $23 |
| Carisoprodol | 22 | $451 | $21 |
| Morphine Sulfate Er | 23 | $427 | $19 |
| Lidocaine-Prilocaine | 27 | $420 | $16 |
| Ondansetron | 21 | $234 | $11 |
| Tamsulosin | 18 | $229 | $13 |
| Venlafaxine | 13 | $225 | $17 |
| Famotidine | 31 | $212 | $7 |
| Amlodipine Besylate | 35 | $209 | $6 |
| Trazodone | 16 | $209 | $13 |
| Sulfamethoxazole-Trimethoprim | 44 | $203 | $5 |
| Omeprazole | 20 | $194 | $10 |
| Amitriptyline | 15 | $178 | $12 |
| Warfarin | 18 | $151 | $8 |
| Pantoprazole | 19 | $134 | $7 |
| Allopurinol | 11 | $126 | $11 |
| Alendronate | 14 | $53 | $4 |
| Diazepam | 26 | $49 | $2 |
| Simvastatin | 11 | $14 | $1 |
2022: 66 drugs
| Revlimid | 90 | $1,369,567 | $15,217 |
| Ibrance | 39 | $574,494 | $14,731 |
| Pomalyst | 25 | $544,195 | $21,768 |
| Jakafi | 31 | $521,429 | $16,820 |
| Lynparza | 22 | $370,528 | $16,842 |
| Xtandi | 21 | $267,632 | $12,744 |
| Tagrisso | 15 | $263,323 | $17,555 |
| Lenalidomide | 16 | $235,300 | $14,706 |
| Imbruvica | 15 | $227,006 | $15,134 |
| Sprycel | 14 | $222,816 | $15,915 |
| Verzenio | 15 | $205,098 | $13,673 |
| Promacta | 11 | $134,843 | $12,258 |
| Mekinist | 11 | $92,781 | $8,435 |
| Deferasirox | 11 | $62,086 | $5,644 |
| Tafinlar | 11 | $56,421 | $5,129 |
| Eliquis | 82 | $46,392 | $566 |
| Imatinib Mesylate | 19 | $35,807 | $1,885 |
| Abiraterone Acetate | 15 | $31,486 | $2,099 |
| Hydrocodone-Acetaminophen | 335 | $17,698 | $53 |
| Xarelto | 26 | $11,162 | $429 |
| Letrozole | 213 | $9,302 | $44 |
| Exemestane | 18 | $6,516 | $362 |
| Fentanyl | 32 | $4,465 | $140 |
| Methadone | 35 | $2,590 | $74 |
| Lamivudine Hbv | 12 | $2,470 | $206 |
| Megestrol Acetate | 45 | $2,423 | $54 |
| Alprazolam | 77 | $2,240 | $29 |
| Hydromorphone | 54 | $2,180 | $40 |
| Oxycodone | 35 | $2,009 | $57 |
| Hydroxyurea | 74 | $1,487 | $20 |
| Anastrozole | 26 | $1,314 | $51 |
| Baclofen | 19 | $1,263 | $66 |
| Morphine Sulfate Er | 34 | $1,253 | $37 |
| Gabapentin | 48 | $1,199 | $25 |
| Acyclovir | 49 | $1,144 | $23 |
| Lorazepam | 100 | $1,129 | $11 |
| Dexamethasone | 50 | $986 | $20 |
| Bicalutamide | 46 | $910 | $20 |
| Ondansetron Odt | 32 | $840 | $26 |
| Oxycodone-Acetaminophen | 56 | $838 | $15 |
| Tamoxifen Citrate | 22 | $795 | $36 |
| Albuterol Sulfate Hfa | 16 | $715 | $45 |
| Prochlorperazine Maleate | 47 | $665 | $14 |
| Levothyroxine | 37 | $610 | $16 |
| Carisoprodol | 28 | $542 | $19 |
| Prednisone | 58 | $533 | $9 |
| Morphine Sulfate | 16 | $525 | $33 |
| Diphenoxylate-Atropine | 13 | $524 | $40 |
| Zolpidem | 41 | $475 | $12 |
| Lidocaine-Prilocaine | 21 | $404 | $19 |
| Ondansetron | 19 | $343 | $18 |
| Venlafaxine Hcl Er | 22 | $307 | $14 |
| Sulfamethoxazole-Trimethoprim | 40 | $241 | $6 |
| Potassium Chloride | 23 | $192 | $8 |
| Amlodipine Besylate | 41 | $142 | $3 |
| Trazodone | 18 | $142 | $8 |
| Propranolol | 12 | $127 | $11 |
| Omeprazole | 13 | $121 | $9 |
| Tamsulosin | 11 | $115 | $10 |
| Allopurinol | 12 | $83 | $7 |
| Famotidine | 25 | $79 | $3 |
| Quinapril | 13 | $62 | $5 |
| Alendronate | 12 | $45 | $4 |
| Pantoprazole | 13 | $42 | $3 |
| Diazepam | 15 | $30 | $2 |
| Simvastatin | 13 | $22 | $2 |
2021: 62 drugs
| Revlimid | 103 | $1,719,306 | $16,692 |
| Xtandi | 55 | $684,908 | $12,453 |
| Ibrance | 39 | $533,393 | $13,677 |
| Lynparza | 26 | $459,665 | $17,679 |
| Jakafi | 16 | $252,531 | $15,783 |
| Verzenio | 16 | $220,996 | $13,812 |
| Sprycel | 13 | $208,389 | $16,030 |
| Lonsurf | 12 | $196,869 | $16,406 |
| Calquence | 11 | $157,293 | $14,299 |
| Erlotinib | 13 | $67,389 | $5,184 |
| Deferasirox | 11 | $62,086 | $5,644 |
| Imatinib Mesylate | 20 | $55,031 | $2,752 |
| Eliquis | 51 | $24,385 | $478 |
| Hydrocodone-Acetaminophen | 407 | $17,437 | $43 |
| Xarelto | 23 | $12,770 | $555 |
| Letrozole | 258 | $7,676 | $30 |
| Exemestane | 33 | $5,391 | $163 |
| Movantik | 13 | $4,696 | $361 |
| Hydroxyurea | 109 | $3,775 | $35 |
| Lamivudine Hbv | 13 | $2,675 | $206 |
| Oxycodone | 47 | $2,628 | $56 |
| Hydromorphone | 54 | $2,254 | $42 |
| Methadone | 30 | $2,224 | $74 |
| Anastrozole | 51 | $1,541 | $30 |
| Morphine Sulfate Er | 41 | $1,514 | $37 |
| Alprazolam | 67 | $1,422 | $21 |
| Tamoxifen Citrate | 33 | $1,358 | $41 |
| Prochlorperazine Maleate | 83 | $1,355 | $16 |
| Gabapentin | 90 | $1,255 | $14 |
| Megestrol Acetate | 35 | $1,206 | $34 |
| Oxycodone-Acetaminophen | 43 | $1,140 | $27 |
| Bicalutamide | 29 | $1,030 | $36 |
| Fentanyl | 16 | $934 | $58 |
| Lorazepam | 89 | $923 | $10 |
| Dexamethasone | 41 | $832 | $20 |
| Morphine Sulfate | 21 | $798 | $38 |
| Ondansetron Odt | 30 | $713 | $24 |
| Baclofen | 13 | $685 | $53 |
| Ondansetron | 40 | $674 | $17 |
| Methotrexate | 16 | $541 | $34 |
| Levothyroxine | 28 | $489 | $17 |
| Diphenoxylate-Atropine | 13 | $472 | $36 |
| Zolpidem | 36 | $446 | $12 |
| Venlafaxine Hcl Er | 32 | $435 | $14 |
| Carisoprodol | 12 | $427 | $36 |
| Lidocaine-Prilocaine | 20 | $405 | $20 |
| Acetaminophen-Codeine | 15 | $371 | $25 |
| Prednisone | 37 | $349 | $9 |
| Acyclovir | 15 | $194 | $13 |
| Allopurinol | 24 | $191 | $8 |
| Amitriptyline | 12 | $188 | $16 |
| Trazodone | 23 | $187 | $8 |
| Hydroxyzine | 17 | $184 | $11 |
| Amlodipine Besylate | 42 | $164 | $4 |
| Pantoprazole | 24 | $160 | $7 |
| Sulfamethoxazole-Trimethoprim | 20 | $88 | $4 |
| Famotidine | 26 | $83 | $3 |
| Metoclopramide | 16 | $75 | $5 |
| Quinapril | 11 | $63 | $6 |
| Diazepam | 22 | $55 | $2 |
| Alendronate | 13 | $52 | $4 |
| Hydrochlorothiazide | 19 | $45 | $2 |
2020: 58 drugs
| Revlimid | 94 | $1,498,441 | $15,941 |
| Lynparza | 20 | $385,229 | $19,261 |
| Tagrisso | 21 | $340,641 | $16,221 |
| Xtandi | 27 | $338,303 | $12,530 |
| Jakafi | 20 | $291,155 | $14,558 |
| Ibrance | 22 | $287,528 | $13,069 |
| Tasigna | 15 | $229,136 | $15,276 |
| Sprycel | 13 | $173,471 | $13,344 |
| Promacta | 12 | $119,916 | $9,993 |
| Imatinib Mesylate | 23 | $89,879 | $3,908 |
| Erlotinib | 15 | $42,945 | $2,863 |
| Eliquis | 31 | $13,477 | $435 |
| Hydrocodone-Acetaminophen | 367 | $13,172 | $36 |
| Xarelto | 18 | $12,193 | $677 |
| Letrozole | 292 | $6,520 | $22 |
| Movantik | 13 | $4,433 | $341 |
| Exemestane | 21 | $3,833 | $183 |
| Lamivudine Hbv | 12 | $2,470 | $206 |
| Hydroxyurea | 62 | $2,436 | $39 |
| Oxycodone | 72 | $2,386 | $33 |
| Morphine Sulfate Er | 43 | $1,727 | $40 |
| Megestrol Acetate | 36 | $1,591 | $44 |
| Prochlorperazine Maleate | 82 | $1,397 | $17 |
| Methadone | 57 | $1,373 | $24 |
| Oxycodone-Acetaminophen | 40 | $1,327 | $33 |
| Gabapentin | 100 | $1,281 | $13 |
| Anastrozole | 67 | $1,198 | $18 |
| Ondansetron | 64 | $1,144 | $18 |
| Bicalutamide | 31 | $1,086 | $35 |
| Hydromorphone | 29 | $1,036 | $36 |
| Tamoxifen Citrate | 16 | $770 | $48 |
| Morphine Sulfate | 22 | $710 | $32 |
| Dexamethasone | 27 | $675 | $25 |
| Lorazepam | 94 | $661 | $7 |
| Venlafaxine Hcl Er | 35 | $624 | $18 |
| Baclofen | 11 | $622 | $57 |
| Alprazolam | 40 | $593 | $15 |
| Potassium Chloride | 14 | $556 | $40 |
| Losartan-Hydrochlorothiazide | 11 | $541 | $49 |
| Diphenoxylate-Atropine | 16 | $495 | $31 |
| Lidocaine-Prilocaine | 24 | $465 | $19 |
| Hydroxyzine | 23 | $260 | $11 |
| Ondansetron Odt | 16 | $253 | $16 |
| Levothyroxine | 11 | $233 | $21 |
| Famotidine | 31 | $201 | $6 |
| Prednisone | 22 | $192 | $9 |
| Zolpidem | 30 | $164 | $5 |
| Carisoprodol | 18 | $155 | $9 |
| Trazodone | 19 | $149 | $8 |
| Allopurinol | 13 | $147 | $11 |
| Pantoprazole | 22 | $146 | $7 |
| Amlodipine Besylate | 25 | $131 | $5 |
| Acyclovir | 14 | $117 | $8 |
| Quinapril | 11 | $87 | $8 |
| Diazepam | 23 | $72 | $3 |
| Losartan | 12 | $64 | $5 |
| Alendronate | 12 | $47 | $4 |
| Hydrochlorothiazide | 14 | $46 | $3 |
2019: 52 drugs
| Revlimid | 90 | $1,202,756 | $13,364 |
| Jakafi | 24 | $335,218 | $13,967 |
| Xtandi | 26 | $315,747 | $12,144 |
| Pomalyst | 18 | $312,943 | $17,386 |
| Ibrance | 22 | $274,629 | $12,483 |
| Tagrisso | 15 | $233,111 | $15,541 |
| Tasigna | 14 | $196,081 | $14,006 |
| Promacta | 13 | $118,509 | $9,116 |
| Jadenu | 11 | $104,966 | $9,542 |
| Imatinib Mesylate | 27 | $61,147 | $2,265 |
| Zarxio | 15 | $35,465 | $2,364 |
| Hydrocodone-Acetaminophen | 306 | $11,168 | $36 |
| Xarelto | 18 | $9,159 | $509 |
| Letrozole | 230 | $4,837 | $21 |
| Lamivudine Hbv | 12 | $3,156 | $263 |
| Oxycodone | 98 | $2,973 | $30 |
| Morphine Sulfate Er | 52 | $2,501 | $48 |
| Hydroxyurea | 55 | $2,451 | $45 |
| Dexamethasone | 49 | $1,335 | $27 |
| Gabapentin | 76 | $1,253 | $16 |
| Megestrol Acetate | 36 | $1,119 | $31 |
| Tamoxifen Citrate | 28 | $1,067 | $38 |
| Hydromorphone | 33 | $1,048 | $32 |
| Methadone | 44 | $1,044 | $24 |
| Exemestane | 12 | $984 | $82 |
| Ondansetron | 59 | $963 | $16 |
| Lorazepam | 89 | $816 | $9 |
| Prochlorperazine Maleate | 76 | $800 | $11 |
| Estradiol | 11 | $798 | $73 |
| Oxycodone-Acetaminophen | 19 | $771 | $41 |
| Alprazolam | 57 | $652 | $11 |
| Anastrozole | 32 | $640 | $20 |
| Diphenoxylate-Atropine | 19 | $505 | $27 |
| Morphine Sulfate | 12 | $483 | $40 |
| Lidocaine-Prilocaine | 22 | $436 | $20 |
| Fluconazole | 12 | $422 | $35 |
| Potassium Chloride | 13 | $368 | $28 |
| Bicalutamide | 12 | $358 | $30 |
| Prednisone | 39 | $357 | $9 |
| Pantoprazole | 39 | $338 | $9 |
| Amoxicillin-Clavulanate Potass | 11 | $318 | $29 |
| Nystatin | 15 | $308 | $21 |
| Acyclovir | 28 | $263 | $9 |
| Venlafaxine Hcl Er | 17 | $202 | $12 |
| Amlodipine Besylate | 45 | $174 | $4 |
| Lidocaine Hcl Viscous | 19 | $168 | $9 |
| Trazodone | 18 | $153 | $9 |
| Diazepam | 33 | $139 | $4 |
| Carisoprodol | 24 | $136 | $6 |
| Zolpidem | 20 | $125 | $6 |
| Famotidine | 20 | $91 | $5 |
| Metoclopramide | 11 | $53 | $5 |
2018: 51 drugs
| Revlimid | 96 | $1,379,697 | $14,372 |
| Pomalyst | 38 | $604,490 | $15,908 |
| Ibrance | 28 | $339,298 | $12,118 |
| Jakafi | 23 | $273,792 | $11,904 |
| Tasigna | 13 | $168,588 | $12,968 |
| Xtandi | 15 | $159,015 | $10,601 |
| Sprycel | 12 | $157,027 | $13,086 |
| Promacta | 14 | $122,846 | $8,775 |
| Jadenu | 11 | $104,611 | $9,510 |
| Imatinib Mesylate | 12 | $69,619 | $5,802 |
| Zarxio | 22 | $52,797 | $2,400 |
| Hydrocodone-Acetaminophen | 311 | $12,954 | $42 |
| Letrozole | 284 | $4,173 | $15 |
| Enoxaparin | 16 | $3,773 | $236 |
| Oxycodone | 90 | $2,625 | $29 |
| Hydroxyurea | 52 | $2,271 | $44 |
| Tamoxifen Citrate | 27 | $1,876 | $69 |
| Dexamethasone | 54 | $1,525 | $28 |
| Megestrol Acetate | 43 | $1,271 | $30 |
| Gabapentin | 87 | $1,216 | $14 |
| Morphine Sulfate Er | 20 | $985 | $49 |
| Hydromorphone | 42 | $914 | $22 |
| Diphenoxylate-Atropine | 21 | $845 | $40 |
| Bicalutamide | 20 | $777 | $39 |
| Ondansetron | 53 | $752 | $14 |
| Prochlorperazine Maleate | 67 | $732 | $11 |
| Morphine Sulfate | 12 | $650 | $54 |
| Lorazepam | 70 | $632 | $9 |
| Duloxetine | 15 | $624 | $42 |
| Alprazolam | 63 | $621 | $10 |
| Methadone | 34 | $542 | $16 |
| Prednisone | 35 | $523 | $15 |
| Potassium Chloride | 21 | $375 | $18 |
| Acyclovir | 33 | $365 | $11 |
| Pantoprazole | 51 | $363 | $7 |
| Lidocaine-Prilocaine | 21 | $361 | $17 |
| Anastrozole | 15 | $254 | $17 |
| Venlafaxine Hcl Er | 13 | $210 | $16 |
| Cyclobenzaprine | 27 | $207 | $8 |
| Levothyroxine | 11 | $178 | $16 |
| Zolpidem | 21 | $131 | $6 |
| Furosemide | 25 | $103 | $4 |
| Sertraline | 13 | $100 | $8 |
| Hydrochlorothiazide | 14 | $96 | $7 |
| Lactulose | 14 | $96 | $7 |
| Baclofen | 14 | $93 | $7 |
| Metoclopramide | 14 | $85 | $6 |
| Diazepam | 17 | $84 | $5 |
| Amlodipine Besylate | 21 | $66 | $3 |
| Famotidine | 16 | $52 | $3 |
| Trazodone | 12 | $44 | $4 |
2017: 48 drugs
| Revlimid | 77 | $1,024,613 | $13,307 |
| Pomalyst | 32 | $419,788 | $13,118 |
| Ibrance | 23 | $257,011 | $11,174 |
| Promacta | 21 | $198,100 | $9,433 |
| Sprycel | 16 | $189,941 | $11,871 |
| Xtandi | 17 | $172,745 | $10,161 |
| Zytiga | 12 | $115,062 | $9,589 |
| Xifaxan | 11 | $21,953 | $1,996 |
| Hydrocodone-Acetaminophen | 280 | $9,324 | $33 |
| Letrozole | 315 | $5,367 | $17 |
| Hydroxyurea | 61 | $1,791 | $29 |
| Hydromorphone | 46 | $1,366 | $30 |
| Oxycodone | 35 | $1,343 | $38 |
| Megestrol Acetate | 41 | $1,214 | $30 |
| Tamoxifen Citrate | 33 | $1,001 | $30 |
| Ranitidine | 12 | $953 | $79 |
| Morphine Sulfate Er | 17 | $915 | $54 |
| Duloxetine | 20 | $865 | $43 |
| Bicalutamide | 40 | $862 | $22 |
| Lorazepam | 81 | $768 | $9 |
| Methadone | 31 | $639 | $21 |
| Gabapentin | 61 | $633 | $10 |
| Prednisone | 45 | $631 | $14 |
| Amitriptyline | 25 | $628 | $25 |
| Dexamethasone | 44 | $618 | $14 |
| Diphenoxylate-Atropine | 16 | $577 | $36 |
| Potassium Chloride | 13 | $524 | $40 |
| Prochlorperazine Maleate | 46 | $460 | $10 |
| Anastrozole | 29 | $428 | $15 |
| Ondansetron | 25 | $415 | $17 |
| Lidocaine-Prilocaine | 11 | $279 | $25 |
| Alprazolam | 39 | $269 | $7 |
| Pantoprazole | 31 | $259 | $8 |
| Ibu | 13 | $216 | $17 |
| Nystatin | 13 | $143 | $11 |
| Furosemide | 18 | $117 | $7 |
| Lactulose | 37 | $113 | $3 |
| Allopurinol | 13 | $112 | $9 |
| Carisoprodol | 14 | $104 | $7 |
| Azithromycin | 14 | $103 | $7 |
| Cyclobenzaprine | 28 | $96 | $3 |
| Lidocaine Hcl Viscous | 11 | $94 | $9 |
| Hydrochlorothiazide | 23 | $86 | $4 |
| Omeprazole | 11 | $65 | $6 |
| Zolpidem | 18 | $60 | $3 |
| Famotidine | 11 | $42 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $41 | $4 |
| Diazepam | 14 | $37 | $3 |
2016: 53 drugs
| Revlimid | 41 | $451,303 | $11,007 |
| Pomalyst | 27 | $352,380 | $13,051 |
| Zytiga | 25 | $214,400 | $8,576 |
| Xtandi | 15 | $139,121 | $9,275 |
| Sprycel | 12 | $130,080 | $10,840 |
| Promacta | 14 | $129,721 | $9,266 |
| Ibrance | 11 | $114,619 | $10,420 |
| Jadenu | 15 | $107,714 | $7,181 |
| Xifaxan | 11 | $20,566 | $1,870 |
| Hydrocodone-Acetaminophen | 296 | $15,804 | $53 |
| Letrozole | 307 | $6,080 | $20 |
| Fentanyl | 22 | $2,913 | $132 |
| Anagrelide | 12 | $2,438 | $203 |
| Oxycodone | 44 | $1,977 | $45 |
| Hydroxyurea | 63 | $1,732 | $27 |
| Fluconazole | 23 | $1,467 | $64 |
| Anastrozole | 27 | $1,138 | $42 |
| Hydromorphone | 42 | $1,077 | $26 |
| Megestrol Acetate | 49 | $1,032 | $21 |
| Prednisone | 60 | $991 | $17 |
| Tamoxifen Citrate | 44 | $988 | $22 |
| Lorazepam | 148 | $987 | $7 |
| Morphine Sulfate Er | 16 | $910 | $57 |
| Dexamethasone | 61 | $899 | $15 |
| Prochlorperazine Maleate | 54 | $640 | $12 |
| Bicalutamide | 24 | $626 | $26 |
| Gabapentin | 56 | $599 | $11 |
| Methadone | 28 | $599 | $21 |
| Diphenoxylate-Atropine | 16 | $568 | $35 |
| Duloxetine | 15 | $500 | $33 |
| Amitriptyline | 17 | $482 | $28 |
| Potassium Chloride | 17 | $383 | $23 |
| Acyclovir | 21 | $296 | $14 |
| Nystatin | 13 | $292 | $22 |
| Allopurinol | 26 | $270 | $10 |
| Pantoprazole | 33 | $259 | $8 |
| Sulfamethoxazole-Trimethoprim | 31 | $254 | $8 |
| Acetaminophen-Codeine | 14 | $238 | $17 |
| Levothyroxine | 11 | $202 | $18 |
| Furosemide | 24 | $181 | $8 |
| Venlafaxine Hcl Er | 19 | $162 | $9 |
| Metoclopramide | 12 | $131 | $11 |
| Omeprazole | 16 | $111 | $7 |
| Ibuprofen | 11 | $109 | $10 |
| Alprazolam | 24 | $109 | $5 |
| Azithromycin | 15 | $102 | $7 |
| Zolpidem | 30 | $102 | $3 |
| Carisoprodol | 13 | $79 | $6 |
| Levofloxacin | 11 | $78 | $7 |
| Lactulose | 18 | $76 | $4 |
| Atorvastatin | 11 | $67 | $6 |
| Temazepam | 16 | $64 | $4 |
| Cyclobenzaprine | 19 | $60 | $3 |
2015: 44 drugs
| Revlimid | 35 | $389,741 | $11,135 |
| Gleevec | 20 | $192,147 | $9,607 |
| Xtandi | 18 | $159,516 | $8,862 |
| Sprycel | 12 | $119,767 | $9,981 |
| Promacta | 12 | $105,706 | $8,809 |
| Procrit | 11 | $37,210 | $3,383 |
| Hydrocodone-Acetaminophen | 302 | $16,785 | $56 |
| Letrozole | 270 | $5,459 | $20 |
| Proair Hfa | 16 | $2,925 | $183 |
| Lidocaine | 12 | $2,879 | $240 |
| Oxycodone | 68 | $2,816 | $41 |
| Fentanyl | 26 | $2,459 | $95 |
| Morphine Sulfate Er | 28 | $2,325 | $83 |
| Anagrelide | 13 | $2,153 | $166 |
| Modafinil | 11 | $1,912 | $174 |
| Hydroxyurea | 61 | $1,648 | $27 |
| Anastrozole | 58 | $1,554 | $27 |
| Lorazepam | 167 | $1,453 | $9 |
| Duloxetine | 14 | $1,145 | $82 |
| Megestrol Acetate | 44 | $1,058 | $24 |
| Prochlorperazine Maleate | 73 | $1,030 | $14 |
| Hydromorphone | 39 | $922 | $24 |
| Bicalutamide | 27 | $859 | $32 |
| Carisoprodol | 35 | $802 | $23 |
| Methadone | 30 | $774 | $26 |
| Morphine Sulfate | 25 | $760 | $30 |
| Tamoxifen Citrate | 36 | $703 | $20 |
| Dexamethasone | 41 | $457 | $11 |
| Amitriptyline | 16 | $448 | $28 |
| Fluconazole | 11 | $376 | $34 |
| Prednisone | 26 | $360 | $14 |
| Promethazine | 46 | $283 | $6 |
| Potassium Chloride | 19 | $243 | $13 |
| Pantoprazole | 24 | $235 | $10 |
| Nystatin | 12 | $212 | $18 |
| Allopurinol | 18 | $176 | $10 |
| Furosemide | 42 | $170 | $4 |
| Zolpidem | 23 | $158 | $7 |
| Omeprazole | 18 | $132 | $7 |
| Azithromycin | 14 | $95 | $7 |
| Alprazolam | 22 | $77 | $4 |
| Amlodipine Besylate | 19 | $74 | $4 |
| Temazepam | 17 | $72 | $4 |
| Cyclobenzaprine | 13 | $44 | $3 |
2014: 45 drugs
| Revlimid | 48 | $372,374 | $7,758 |
| Exjade | 15 | $180,070 | $12,005 |
| Gleevec | 23 | $158,781 | $6,904 |
| Promacta | 20 | $147,638 | $7,382 |
| Nexavar | 13 | $140,491 | $10,807 |
| Tarceva | 19 | $121,137 | $6,376 |
| Hydrocodone-Acetaminophen | 379 | $12,195 | $32 |
| Letrozole | 214 | $8,215 | $38 |
| Lidocaine | 22 | $5,315 | $242 |
| Lyrica | 11 | $2,963 | $269 |
| Morphine Sulfate Er | 36 | $2,538 | $70 |
| Anastrozole | 68 | $2,359 | $35 |
| Proair Hfa | 21 | $2,266 | $108 |
| Prochlorperazine Maleate | 88 | $2,115 | $24 |
| Duloxetine | 11 | $1,923 | $175 |
| Fentanyl | 12 | $1,809 | $151 |
| Oxycodone | 36 | $1,718 | $48 |
| Megestrol Acetate | 57 | $1,662 | $29 |
| Hydroxyurea | 47 | $1,590 | $34 |
| Lorazepam | 159 | $1,494 | $9 |
| Carisoprodol | 35 | $1,261 | $36 |
| Hydromorphone | 51 | $1,151 | $23 |
| Morphine Sulfate | 39 | $1,110 | $28 |
| Ondansetron Odt | 20 | $591 | $30 |
| Methadone | 35 | $582 | $17 |
| Diphenoxylate-Atropine | 28 | $569 | $20 |
| Nystatin | 21 | $559 | $27 |
| Bicalutamide | 25 | $542 | $22 |
| Dexamethasone | 44 | $498 | $11 |
| Prednisone | 37 | $363 | $10 |
| Gabapentin | 30 | $326 | $11 |
| Tamoxifen Citrate | 16 | $282 | $18 |
| Omeprazole | 19 | $259 | $14 |
| Potassium Chloride | 13 | $223 | $17 |
| Pantoprazole | 13 | $223 | $17 |
| Zolpidem | 31 | $220 | $7 |
| Isosorbide Mononitrate Er | 13 | $211 | $16 |
| Furosemide | 48 | $165 | $3 |
| Levofloxacin | 17 | $161 | $9 |
| Allopurinol | 24 | $125 | $5 |
| Alprazolam | 15 | $118 | $8 |
| Azithromycin | 14 | $107 | $8 |
| Temazepam | 19 | $79 | $4 |
| Diazepam | 15 | $67 | $4 |
| Hydrochlorothiazide | 15 | $44 | $3 |
2013: 47 drugs
| Revlimid | 74 | $507,614 | $6,860 |
| Gleevec | 24 | $156,095 | $6,504 |
| Tarceva | 23 | $133,753 | $5,815 |
| Exjade | 11 | $120,186 | $10,926 |
| Thalomid | 13 | $93,831 | $7,218 |
| Enoxaparin | 37 | $39,566 | $1,069 |
| Letrozole | 237 | $10,086 | $43 |
| Hydrocodone-Acetaminophen | 357 | $9,848 | $28 |
| Lidoderm | 11 | $3,974 | $361 |
| Anastrozole | 112 | $3,754 | $34 |
| Megestrol Acetate | 80 | $3,588 | $45 |
| Xarelto | 11 | $3,295 | $300 |
| Morphine Sulfate Er | 57 | $2,922 | $51 |
| Cymbalta | 12 | $2,515 | $210 |
| Fentanyl | 18 | $2,150 | $119 |
| Oxycodone | 71 | $2,131 | $30 |
| Hydroxyurea | 48 | $1,794 | $37 |
| Lorazepam | 154 | $1,688 | $11 |
| Lidocaine | 11 | $1,584 | $144 |
| Hydromorphone | 37 | $940 | $25 |
| Morphine Sulfate | 31 | $939 | $30 |
| Premarin | 11 | $931 | $85 |
| Prochlorperazine Maleate | 76 | $818 | $11 |
| Nystatin | 17 | $554 | $33 |
| Methadone | 45 | $545 | $12 |
| Ondansetron | 16 | $501 | $31 |
| Gabapentin | 25 | $486 | $19 |
| Omeprazole | 31 | $434 | $14 |
| Labetalol | 11 | $412 | $37 |
| Dexamethasone | 44 | $396 | $9 |
| Warfarin | 26 | $346 | $13 |
| Carisoprodol | 34 | $304 | $9 |
| Alprazolam | 37 | $295 | $8 |
| Allopurinol | 37 | $244 | $7 |
| Prednisone | 42 | $243 | $6 |
| Ibuprofen | 17 | $200 | $12 |
| Lactulose | 17 | $188 | $11 |
| Amlodipine Besylate | 19 | $188 | $10 |
| Isosorbide Mononitrate Er | 11 | $154 | $14 |
| Famotidine | 17 | $146 | $9 |
| Venlafaxine Hcl Er | 11 | $146 | $13 |
| Ranitidine | 11 | $138 | $13 |
| Clopidogrel | 12 | $110 | $9 |
| Azithromycin | 11 | $102 | $9 |
| Furosemide | 30 | $86 | $3 |
| Amitriptyline | 11 | $41 | $4 |
| Folic Acid | 12 | $25 | $2 |
Money from drug and device companies
$2,297 in 2025
| 2025 | 35 | 63 | None | $2,297 |
| 2024 | 26 | 44 | None | $1,529 |
| 2023 | 29 | 52 | None | $1,380 |
| 2022 | 33 | 69 | None | $1,833 |
| 2021 | 40 | 146 | None | $2,794 |
| 2020 | 29 | 61 | $455 | $1,552 |
| 2019 | 21 | 29 | None | $580 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $1,254 | 18 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $104 | 4 payments
|
| Pfizer | Xtandi | $64 | 3 payments
|
| Celgene | Reblozyl | $52 | 2 payments
|
| Genentech USA | Itovebi | $52 | 2 payments
|
| Genzyme | Sarclisa | $51 | 2 payments
|
See all 63 published payments
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-12-30 | Kisqali | $83 |
| Novartis Pharmaceuticals | Meals · 2025-12-17 | Fabhalta | $27 |
| Immunocore | Meals · 2025-12-03 | Kimmtrak | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-11-26 | Kisqali | $83 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-19 | Opdivo | $24 |
| Amgen | Meals · 2025-11-17 | Evenity | $20 |
| Genzyme | Meals · 2025-11-17 | Sarclisa | $26 |
| Genzyme | Meals · 2025-11-17 | Sarclisa | $25 |
| SpringWorks Therapeutics | Meals · 2025-11-10 | Ogsiveo | $38 |
| Gilead Sciences | Meals · 2025-11-04 | Trodelvy | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-03 | Iclusig | $15 |
| Janssen Biotech | Meals · 2025-10-30 | Rybrevant | $42 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-10-23 | Kisqali | $83 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-20 | Tagrisso | $19 |
| Tempus AI | Meals · 2025-09-30 | Xt Cdx | $17 |
| Merck Sharp & Dohme | Meals · 2025-09-29 | Keytruda | $24 |
| Recordati Rare Diseases Inc. | Meals · 2025-09-22 | Enjaymo | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-09-19 | Kisqali | $83 |
| Agios Pharmaceuticals | Meals · 2025-09-08 | Pyrukynd | $22 |
| Daiichi Sankyo | Meals · 2025-08-27 | Datroway | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Fabhalta | $9 |
| Progenics Pharmaceuticals | Meals · 2025-08-06 | Pylarify | $19 |
| Celgene | Meals · 2025-08-04 | Reblozyl | $23 |
| Lilly USA | Meals · 2025-07-28 | Verzenio | $18 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $100 |
| Celgene | Meals · 2025-07-24 | Reblozyl | $29 |
| Merck Sharp & Dohme | Meals · 2025-07-21 | Keytruda | $27 |
| Abbvie | Meals · 2025-07-16 | Venclexta | $18 |
| Geron | Meals · 2025-07-09 | Rytelo | $17 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-08 | Nubeqa | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-03 | Enhertu | $17 |
| Incyte | Meals · 2025-06-25 | Jakafi | $29 |
| Ipsen Biopharmaceuticals | Meals · 2025-06-23 | Onivyde | $14 |
| Fennec Pharmaceuticals | Meals · 2025-06-23 | Fyarro | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $100 |
| Jazz Pharmaceuticals | Meals · 2025-06-11 | Ziihera | $40 |
| Novartis Pharmaceuticals | Meals · 2025-06-09 | Scemblix | $15 |
| Deciphera Pharmaceuticals | Meals · 2025-06-04 | Qinlock | $35 |
| Genentech USA | Meals · 2025-06-02 | Itovebi | $20 |
| Servier Pharmaceuticals | Meals · 2025-05-21 | Voranigo | $24 |
| Novartis Pharmaceuticals | Meals · 2025-05-20 | Pluvicto | $30 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $100 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-06 | Opdivo | $25 |
| Kite Pharma | Meals · 2025-05-06 | Yescarta | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-04-28 | Libtayo | $17 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $100 |
| Pfizer | Meals · 2025-04-21 | Elrexfio | $22 |
| Rigel Pharmaceuticals | Meals · 2025-04-16 | Tavalisse | $24 |
| Pfizer | Meals · 2025-04-14 | Xtandi | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-09 | Opdivo | $32 |
| Pfizer | Meals · 2025-04-04 | Xtandi | $24 |
| Novartis Pharmaceuticals | Meals · 2025-04-01 | Kisqali | $21 |
| Eisai | Meals · 2025-04-01 | Lenvima | $17 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-03-24 | Scemblix | $22 |
| Abbvie | Meals · 2025-02-24 | Imbruvica | $23 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $100 |
| EMD Serono | Meals · 2025-02-11 | None | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-31 | Opdivo | $23 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $100 |
| Spectrum Pharmaceuticals | Meals · 2025-01-16 | Rolvedon | $20 |
| Genentech USA | Meals · 2025-01-15 | Itovebi | $32 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,529
| Novartis Pharmaceuticals | Kisqali | $541 | 9 payments
|
| Boston Scientific | Axios | $109 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $92 | 4 payments
|
| Lilly USA | Verzenio | $79 | 1 payment
|
| Celgene | Reblozyl | $72 | 3 payments
|
| Janssen Biotech | Erleada | $70 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $53 | 2 payments
|
| Pfizer | Ibrance | $48 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $38 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $34 | 1 payment
|
| Genentech USA | Venclexta | $32 | 1 payment
|
| Abbvie | Imbruvica | $29 | 1 payment
|
| Blueprint Medicines | Ayvakit | $29 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $29 | 1 payment
|
| PharmaEssentia USA | Besremi | $28 | 1 payment
|
| Incyte | Jakafi | $28 | 1 payment
|
| Stemline Therapeutics | Orserdu | $28 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $27 | 1 payment
|
| Array Biopharma | Lorbrena | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $24 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $23 | 1 payment
|
| Aadi Bioscience | Fyarro | $21 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $20 | 1 payment
|
| Astellas Pharma US | Padcev | $19 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $18 | 1 payment
|
| BeiGene USA | Brukinsa | $14 | 1 payment
|
2023: $1,380
| Novartis Pharmaceuticals | Tasigna | $317 | 6 payments
|
| Seagen | Padcev | $173 | 4 payments
|
| Genzyme | Sarclisa | $114 | 5 payments
|
| Lilly USA | Verzenio | $70 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $68 | 3 payments
|
| Amgen | Lumakras | $53 | 3 payments
|
| Pfizer | Ibrance | $46 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $45 | 2 payments
|
| Servier Pharmaceuticals | Tibsovo | $39 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $33 | 2 payments
|
| Medtronic | Osteocool Rf Ablation System | $33 | 1 payment
|
| EMD Serono | Bavencio | $33 | 2 payments
|
| GlaxoSmithKline | Zejula | $29 | 1 payment
|
| Mirati Therapeutics | Krazati | $26 | 1 payment
|
| PharmaEssentia USA | Besremi | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $24 | 1 payment
|
| AbbVie | Venclexta | $24 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $24 | 1 payment
|
| Apellis Pharmaceuticals | None | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $22 | 1 payment
|
| Janssen Biotech | Darzalex | $20 | 1 payment
|
| Genentech USA | Polivy | $20 | 1 payment
|
| MorphoSys US | Monjuvi | $19 | 1 payment
|
| Kyowa Kirin | Poteligeo | $18 | 1 payment
|
| BeiGene USA | Brukinsa | $18 | 1 payment
|
| Array Biopharma | Lorbrena | $18 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $18 | 1 payment
|
| Kite Pharma | Yescarta | $15 | 1 payment
|
| Genmab U.S. | Epkinly | $15 | 1 payment
|
2022: $1,833
| Novartis Pharmaceuticals | Kisqali | $437 | 9 payments
|
| Amgen | Kyprolis | $243 | 7 payments
|
| Abbvie | Venclexta | $170 | 4 payments
|
| Lilly USA | Cyramza | $90 | 3 payments
|
| Janssen Biotech | Imbruvica | $85 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $77 | 4 payments
|
| Blueprint Medicines | Ayvakit | $59 | 1 payment
|
| Astellas Pharma US | Xtandi | $51 | 3 payments
|
| Pfizer | Xtandi | $50 | 3 payments
|
| Celgene | Pomalyst | $42 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $41 | 2 payments
|
| Genentech USA | Tecentriq | $40 | 4 payments
|
| Myovant Sciences | Orgovyx | $29 | 1 payment
|
| BeiGene USA | Brukinsa | $29 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
| Seagen | Adcetris | $24 | 1 payment
|
| G1 Therapeutics | Cosela | $23 | 1 payment
|
| Array Biopharma | Braftovi | $23 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $23 | 1 payment
|
| GlaxoSmithKline | Zejula | $23 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $22 | 1 payment
|
| Kyowa Kirin | Poteligeo | $21 | 1 payment
|
| Daiichi Sankyo | Enhertu | $20 | 1 payment
|
| GE HealthCare | None | $20 | 1 payment
|
| Kite Pharma | None | $20 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $20 | 1 payment
|
| Sobi | Doptelet | $20 | 1 payment
|
| TG Therapeutics | Ukoniq | $19 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $19 | 1 payment
|
| EMD Serono | None | $18 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $16 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $15 | 1 payment
|
| Secura Bio | Copiktra | $13 | 1 payment
|
2021: $2,794
| Novartis Pharmaceuticals | Kisqali | $1,068 | 13 payments
|
| Astellas Pharma US | Xospata | $220 | 4 payments
|
| Janssen Biotech | Erleada | $176 | 7 payments
|
| Pfizer | Ibrance | $160 | 15 payments
|
| Seagen | Padcev | $137 | 4 payments
|
| Eisai | Lenvima | $76 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $61 | 4 payments
|
| Celgene | Onureg | $55 | 3 payments
|
| Acrotech Biopharma | Beleodaq | $52 | 4 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $52 | 2 payments
|
| Lilly USA | Erbitux | $44 | 2 payments
|
| Myovant Sciences | Orgovyx | $44 | 2 payments
|
| Epizyme | Tazverik | $38 | 2 payments
|
| Genzyme | Jevtana | $37 | 2 payments
|
| Gilead Sciences | Trodelvy | $34 | 2 payments
|
| Heron Therapeutics | Cinvanti | $33 | 2 payments
|
| Kite Pharma | None | $28 | 1 payment
|
| Ge Healthcare | None | $28 | 1 payment
|
| Amgen | Nplate | $28 | 1 payment
|
| Blueprint Medicines | Gavreto | $25 | 1 payment
|
| TerSera Therapeutics | Zoladex | $25 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $25 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $24 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $23 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $22 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $22 | 1 payment
|
| Genentech USA | Perjeta | $22 | 1 payment
|
| Incyte | Monjuvi | $22 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $21 | 1 payment
|
| Secura Bio | Farydak | $20 | 1 payment
|
| Array Biopharma | Braftovi | $20 | 1 payment
|
| Puma Biotechnology | Nerlynx | $19 | 1 payment
|
| MorphoSys US | Monjuvi | $19 | 1 payment
|
| EMD Serono | None | $17 | 1 payment
|
| Stemline Therapeutics | Elzonris | $16 | 1 payment
|
| Sun Pharmaceutical Industries | Yonsa | $16 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $15 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $15 | 1 payment
|
| Exelixis | Cabometyx | $13 | 1 payment
|
2020: $1,552
| Genentech USA | Avastin | $468 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $171 | 5 payments
|
| Pfizer | Ibrance | $128 | 10 payments
|
| Seagen | Tukysa | $96 | 5 payments
|
| Celgene | Onureg | $65 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $61 | 4 payments
|
| Eisai | Lenvima | $58 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $42 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $38 | 2 payments
|
| Kite Pharma | None | $37 | 2 payments
|
| Puma Biotechnology | Nerlynx | $37 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $30 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $28 | 2 payments
|
| Aurobindo Pharma USA | Zevalin | $28 | 2 payments
|
| BeiGene USA | Brukinsa | $27 | 2 payments
|
| Blueprint Medicines | Gavreto | $24 | 1 payment
|
| GlaxoSmithKline | Zejula | $23 | 1 payment
|
| Amgen | Kyprolis | $23 | 1 payment
|
| Clovis Oncology | Rubraca | $20 | 1 payment
|
| Genzyme | Jevtana | $18 | 1 payment
|
| Astellas Pharma US | Padcev | $16 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $15 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $15 | 1 payment
|
| Teva Pharmaceuticals USA | Truxima | $14 | 1 payment
|
| Emmaus Medical | Endari | $14 | 1 payment
|
| Janssen Biotech | Darzalex | $14 | 1 payment
|
| Secura Bio | Farydak | $13 | 1 payment
|
| Lilly USA | Retevmo | $13 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $13 | 1 payment
|
2019: $580
| Celgene | Revlimid | $96 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $53 | 2 payments
|
| Pfizer | Ibrance | $45 | 2 payments
|
| Janssen Biotech | Erleada | $41 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $37 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $33 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $31 | 2 payments
|
| Blue Earth Diagnostics | Axumin | $25 | 1 payment
|
| Astellas Pharma US | Cresemba | $23 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $23 | 1 payment
|
| Eisai | Lenvima | $22 | 1 payment
|
| Puma Biotechnology | Nerlynx | $19 | 1 payment
|
| Lilly USA | Erbitux | $18 | 1 payment
|
| Genzyme | Jevtana | $17 | 1 payment
|
| Genentech USA | Tecentriq | $15 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $15 | 1 payment
|
| Heron Therapeutics | Cinvanti | $15 | 2 payments
|
| Amgen | Neulasta | $14 | 1 payment
|
| Seattle Genetics | Adcetris | $13 | 1 payment
|
| EMD Serono | Bavencio | $12 | 1 payment
|
| Gilead Sciences | None | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Cc-92480 (Bms-986348), Carfilzomib and Dexamethasone (480kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed Or Refractory Multiple Myeloma (Rrmm). · 2025 | Their institution | $37,350 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Cc-92480 (Bms-986348), Carfilzomib and Dexamethasone (480kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed Or Refractory Multiple Myeloma (Rrmm). · 2025 | Their institution | $1,500 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1154326262
- Licence
- CA A70883California A70883: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A708831
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- Po Box 7667, Stockton, CA, 95267
- NPI first listed
- 2005-06-15
- NPI last updated
- 2012-06-25
This is when the NPI record was last certified, not a medical board exam.